Status:
RECRUITING
Deep TMS of Neural Circuits Associated With Stimulant Use Disorder
Lead Sponsor:
Stanford University
Collaborating Sponsors:
VA Palo Alto Health Care System
Conditions:
Methamphetamine Use Disorder
Transcranial Magnetic Stimulation
Eligibility:
All Genders
25-75 years
Phase:
NA
Brief Summary
This study aims to evaluate the efficacy of deep transcranial magnetic stimulation (dTMS) as a treatment for Veterans with a methamphetamine use disorder (MUD).
Detailed Description
To date, TMS has emerged as a promising treatment avenue for addiction and is being tested in clinical trials with some encouraging results. A recent systematic review and meta-analysis highlights tha...
Eligibility Criteria
Inclusion
- Inclusion:
- Must be within the age range of 25-75.
- Participants must meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for moderate to severe MUD (≥4 diagnostic symptoms).
- Participants must be able to obtain a Motor Threshold (MT), which will be determined during the screening process.
- Participants must have an adequately stable condition and environment to enable attendance at scheduled clinic visits.
- Participants must be able to read, verbalize, understand, and voluntarily sign the Informed Consent Form prior to participation in study procedures in English.
- If participants are on a medication regimen for comorbid symptoms, that regimen will be stable for the duration of the study and patient will be willing to remain on this regimen during the treatment phase.
- Participants must be fluent in English
- Exclusion criteria:
- Transcranial magnetic stimulation (TMS) and magnetic resonance imaging (MRI) contraindications: such as a cardiac pacemaker, cochlear implant, or an implanted device (deep brain stimulation, ferromagnetic metal in the head and body, claustrophobia, pregnant or breastfeeding or other ferromagnetic device/object in the head and body within 30 cm of the treatment coil.
- General medical condition, disease, or neurological disorder that interferes with the assessments or participation.
- Unable to safely withdraw, at least two weeks prior to treatment, from medications that increase seizure risk.
- Current substance abuse as determined by positive toxicology screen
- Have a mass lesion, cerebral infarct, or other active CNS disease, including a seizure disorder.
- A recent suicide attempt (defined as within the last 30 days) or presence of current suicidal plan or intent. Patients at risk for suicide will be required to establish a written safety plan involving their primary therapist before entering the study.
- Severe impediment to vision, hearing and/or hand movement, as this is likely to interfere with the ability to follow study protocols.
- Greater than mild traumatic brain injury (defined as greater than 10 minutes loss of consciousness).
- Taking benzodiazepines or neuroleptic medications, or any medication known to alter seizure threshold.
- Acute or unstable chronic illness.
- Current or lifetime history of bipolar disorder or psychosis.
- Participation in another concurrent intervention-based clinical trial.
Exclusion
Key Trial Info
Start Date :
March 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06578429
Start Date
March 15 2025
End Date
December 31 2026
Last Update
September 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Palo Alto Health Care System
Palo Alto, California, United States, 94304